Voyager Therapeutics, a Cambridge, Mass.-based newly formed gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), launched with $45m in Series A financing.
Third Rock Ventures made the investment.
Founded by Krystof Bankiewicz, M.D., Ph.D., Guangping Gao, Ph.D., Mark Kay, M.D., Ph.D., Phillip Zamore, Ph.D., and led by Mark Levin, Interim Chief Executive Officer, and and Philip Reilly, M.D., J.D., Interim Chief Medical Officer (both partners at Third Rock), Voyager is launching with multiple clinical and preclinical product programs for CNS diseases in dire need of effective new therapies, including a Parkinson’s disease program in an ongoing Phase 1b study as well as preclinical programs for a monogenic form of amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.
The company has entered into license and other agreements to access technology and data, including rights to intellectual property related to expressed RNAi technology discovered at UMMS, clinical data related to the Parkinson’s disease program from UCSF, and certain rights to AAV intellectual property developed at Stanford.
FinSMEs
12/02/2014